JPMorgan Chase & Co. 13D and 13G filings for Evolent Health, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-09 1:17 pm Sale |
2024-03-29 | 13G | Evolent Health, Inc. EVH |
J P MORGAN CHASE & CO JPM |
4,679,353 4.000% |
-1,184,177 (-20.20%) |
Filing |
| 2024-01-18 08:19 am Purchase |
2023-12-29 | 13G | Evolent Health, Inc. EVH |
J P MORGAN CHASE & CO JPM |
5,863,530 5.100% |
494,705 (+9.21%) |
Filing |
| 2023-01-20 12:28 pm Sale |
2022-12-30 | 13G | Evolent Health, Inc. EVH |
J P MORGAN CHASE & CO JPM |
5,368,825 5.300% |
-743,415 (-12.16%) |
Filing |
| 2022-01-10 3:02 pm Sale |
2021-12-31 | 13G | Evolent Health, Inc. EVH |
J P MORGAN CHASE & CO JPM |
6,112,240 6.800% |
-422,295 (-6.46%) |
Filing |
| 2021-01-22 10:48 am Purchase |
2020-12-31 | 13G | Evolent Health, Inc. EVH |
J P MORGAN CHASE & CO JPM |
6,534,535 7.600% |
219,365 (+3.47%) |
Filing |